Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLC

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence o...

詳細記述

書誌詳細

主要な著者:	Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Patrice Desmeules, Rosalyn A. Juergens, Natasha B. Leighl, Brandon S. Sheffield, Paul F. Wheatley-Price, Barbara L. Melosky
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-11-01
シリーズ:	Current Oncology
主題:	non-small cell lung cancer <i>MET</i> exon 14 skipping mutations <i>MET</i> amplification <i>MET</i> inhibitors EGFR resistance
オンライン･アクセス:	https://www.mdpi.com/1718-7729/28/6/386
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!